Pharmacologic biomarkers in the development of stratified cancer medicine

Clinical Cancer Research

Volumn 20, Issue 10, 2014, Pages 2525-2529

  Figg, William Douglas ^a   Newell, David R ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CELL DNA; CIRCULATING TUMOR DNA; DOCETAXEL; DOCETAXEL C 11; PACLITAXEL F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DNA; TUMOR MARKER;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER STAGING; CIRCULATING TUMOR CELL; CLINICAL PHARMACOLOGY; DRUG POTENTIATION; DRUG UPTAKE; GENETIC ASSOCIATION; HUMAN; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; PATHOGENESIS; PHARMACODYNAMICS; PHARMACOGENOMICS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; AREA UNDER THE CURVE; BIOLOGICAL MODEL; BLOOD; GENETICS; METABOLIC CLEARANCE RATE; METABOLISM; NEOPLASMS;

ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BIOMARKERS, TUMOR; DNA, NEOPLASM; HUMANS; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; NEOPLASMS;

EID: 84901008744     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0511     Document Type: Article

References (29)

1. Beelen AP, Lewis LD. Clinical pharmacology overview. In:Figg WD, McLeod HL, editors. Handbook of anticancer pharmacokinetics and pharmacodynamics. New York, NY: Springer; 2004. p. 111-27.
2. Hertz DL, McLeod HL. Using pharmacogene polymorphism panels to detect germline pharmacodynamic markers in oncology. Clin Cancer Res 2014;20:2530-40.
3. Kinders R, Ferry-Galow K, Wang L, Srivastava AK, Ji JJ, Parchment RE. Implementation of validated pharmacodynamic assays in multiple laboratories: challenges, successes, and limitations. Clin Cancer Res 2014;20:2578-86.
4. Yap TA, Lorente D, Omlin A, Olmos D, de Bono JS. Circulating tumor cells: a multifunctional biomarker. Clin Cancer Res 2014;20:2553-68.
5. van der Veldt AAM, Lammertsma AA. In vivo imaging as a pharmacodynamic marker. Clin Cancer Res 2014;20:2569-77.
6. Gainor JF, Longo DL, Chabner BA. Pharmacodynamic biomarkers: falling short of the mark? Clin Cancer Res 2014;20:2587-94.
7. Low S-K, Takahashi A, Mushiroda T, Kubo M. Genome-wide association study: a useful tool to identify common genetic variants associated with drug toxicity and efficacy in cancer pharmacogenomics. Clin Cancer Res 2014;20:2541-52.
8. Wagner JA. Overview of biomarkers and surrogate endpoints in drug development. Dis Markers 2002;18:41-6.
9. Parkinson DR, McCormack RT, Keating SM, Gutman SI, Hamilton SR, Mansfield EA, et al. Evidence of clinical utility: an unmet need in molecular diagnostics for patients with cancer. Clin Cancer Res 2014; 20:1428-44.
10. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95.
11. Lee JW, Devanarayan V, Barrett YC, Weiner R, Allinson J, Fountain S, et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res 2006;23:312-28.
12. US Food and Drug Administration. Guidance for industry: bioanalytical method validation.Draft Guidance. 2013. [cited 2014 March]. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM368107.pdf
13. Campion S, Aubrecht J, Boekelheide K, Brewster DW, Vaidya VS, Anderson L, et al. The current status of biomarkers for predicting toxicity. Expert Opin Drug Metab Toxicol. 2013;9:1391-408.
14. US Food and Drug Administration. Guidance for industry: pharmacogenomic data submissions. 2005. [cited 2014 March]. Available from: http://www.fda.gov/ downloads/regulatoryinformation/guidances/ucm126957.pdf 15.
15. US Food and Drug Administration. Guidance for industry and FDA staff. Qualification process for drug development tools. 2014. [cited 2014 March]. Available from: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM230597.pdf
16. King JD, Casavant BP, Lang JM. Rapid translation of circulating tumor cell biomarkers into clinical practice: technology development, clinical needs and regulatory requirements. Lab Chip 2014;14:24-31.
17. Waterton JC, Pylkkanen L. Qualification of imaging biomarkers for oncology drug development. Eur J Cancer 2012;48:409-15.
18. Goodsaid F, Frueh F. Process map proposal for the validation of genomic biomarkers. Pharmacogenomics 2006;7:773-82.
19. Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001;61:1659-65.
20. Bidard FC, Madic J, Mariani P, Piperno-Neumann S, Rampanou A, Servois V, et al. Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma. Int J Cancer 2014;134:1207-13.
21. Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013;368:1199-209.
22. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008;14: 985-90.
23. Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DW, Kaper F, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 2012;4: 136ra68.
24. Shinozaki M, O'Day SJ, Kitago M,Amersi F, Kuo C, KimJ, et al. Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy. ClinCancerRes 2007;13:2068-74.
25. Diaz Jr.L.A., Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012;486:537-40.
26. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012;486:532-6.
27. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early-And late-stage human malignancies. Sci Transl Med 2014;6:224ra24.
28. Misale S, Arena S, Lamba S, Siravegna G, Lallo A, Hobor S, et al. Blockade of EGFR andMEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Sci Transl Med 2014;6:224ra26.
29. Diaz Jr.L.A., Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 2014;32:579-86.